Interleukin-31 acts directly on the hair follicle bulge across species and delays plucking-induced anagen re-entry in mice, according to a study published online October 13, 2026, in the Journal of Investigative Dermatology.

The paper comes from Kosuke Katsuo, Satoshi Nakamizo, Gyohei Egawa, Akihiko Kitoh, Saeko Nakajima, Takaharu Okada and Kenji Kabashima. The group's central finding is anatomical and functional at once: IL-31, a cytokine best known in dermatology for driving pruritus in atopic dermatitis, has a second address — the bulge region of the hair follicle, where epithelial stem cells that cycle hair growth reside.

Why does the bulge matter?

The bulge sits at the insertion point of the arrector pili muscle and holds the keratinocyte stem cells that kick off each new hair cycle. When a follicle re-enters anagen — the active growth phase — those quiescent bulge cells divide first.

The researchers report that IL-31 signaling reaches this compartment in more than one species. That cross-species consistency matters. A single-mouse observation can reflect a strain-specific artifact; a pattern that holds across species suggests the pathway is a conserved feature of follicle biology, not a laboratory curiosity.

What did the functional experiment show?

The team used a plucking model. Plucking hairs is a standard way to synchronize the hair cycle in mice: the trauma pushes follicles into a coordinated regrowth phase.

In this study, IL-31 delayed that plucking-induced anagen. In plain terms, follicles exposed to IL-31 signaling took longer to move from rest into growth. The delay places IL-31 among the growing list of inflammatory cytokines that do not merely accompany skin inflammation but actively reshape hair-cycle timing.

The effect is a delay, not an ablation. The distinction matters clinically. A slowed entry into anagen is the kind of mechanism that could compound over repeated cycles — consistent with the patchy growth suppression clinicians see in inflamed skin — without destroying the follicle itself.

How does this fit the IL-31 story so far?

Dermatology already works with IL-31 clinically. Nemolizumab, an anti-IL-31 receptor A antibody, is approved for prurigo nodularis and has studied use in atopic dermatitis. Until now, the cytokine's claim to fame has been itch.

This paper adds a hair-specific chapter. If IL-31 tonically restrains bulge stem-cell activation, then chronic IL-31 elevation — as in atopic dermatitis or other itchy inflammatory dermatoses — could plausibly feed into the hair-shaft fragility and growth disruption patients report. The study does not test that clinical link directly; it establishes the target tissue and the delay phenotype in mice.

What comes next?

The obvious follow-ups are bulge-cell-intrinsic mechanism work — which receptor subunits the follicle stem cells express, and which downstream pathways stall the quiescence-to-activation switch — plus studies asking whether IL-31 blockade in humans accelerates anagen entry in inflamed scalp. For now, the field has a new, precisely located thread to pull: IL-31 speaks to the stem cell niche that grows hair, and in mice, at least, it tells that niche to wait.